- Home
- AII vs CADL Comparison
AII vs CADL Comparison
Compare AII & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- CADL
- Stock Information
- Founded
- AII 2006
- CADL 1999
- Country
- AII United States
- CADL United States
- Employees
- AII N/A
- CADL N/A
- Industry
- AII Property-Casualty Insurers
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- AII Finance
- CADL Health Care
- Exchange
- AII Nasdaq
- CADL Nasdaq
- Market Cap
- AII 323.7M
- CADL 315.1M
- IPO Year
- AII 2025
- CADL 2021
- Fundamental
- Price
- AII $18.66
- CADL $6.17
- Analyst Decision
- AII Buy
- CADL Strong Buy
- Analyst Count
- AII 3
- CADL 5
- Target Price
- AII $21.50
- CADL $21.40
- AVG Volume (30 Days)
- AII 81.9K
- CADL 990.4K
- Earning Date
- AII 08-12-2025
- CADL 08-12-2025
- Dividend Yield
- AII N/A
- CADL N/A
- EPS Growth
- AII N/A
- CADL N/A
- EPS
- AII 3.19
- CADL N/A
- Revenue
- AII $231,932,000.00
- CADL N/A
- Revenue This Year
- AII $25.16
- CADL N/A
- Revenue Next Year
- AII $34.05
- CADL N/A
- P/E Ratio
- AII $5.87
- CADL N/A
- Revenue Growth
- AII 1.73
- CADL N/A
- 52 Week Low
- AII $15.78
- CADL $3.79
- 52 Week High
- AII $19.45
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- AII N/A
- CADL 48.78
- Support Level
- AII N/A
- CADL $6.11
- Resistance Level
- AII N/A
- CADL $6.40
- Average True Range (ATR)
- AII 0.00
- CADL 0.36
- MACD
- AII 0.00
- CADL -0.10
- Stochastic Oscillator
- AII 0.00
- CADL 7.68
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.